PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
1322666-4	1992	DDTC treatment also increased interleukin-alpha (IL-1 alpha), IL-1 beta, and tumor necrosis factor (TNF) expression in these cells.	Ditiocarb	0-4	interleukin 1 beta	Homo sapiens	62-71	
10564154-8	1999	In contrast to NAC, the metal chelators pyrrolidine dithiocarbamate and diethyldithiocarbamate attenuated IL-1beta-induced NF-kappaB activation but had no effect on intracellular sulfhydryl content.	Ditiocarb	72-94	interleukin 1 beta	Homo sapiens	106-114	
10029158-0	1999	IL-1beta mediates diethyldithiocarbamate-induced granulocyte colony-stimulating factor production and hematopoiesis.	Ditiocarb	18-40	interleukin 1 beta	Homo sapiens	0-8	
10029158-2	1999	The mechanism of DDTC-mediated chemoprotection is believed to involve the induction and release of several cytokines, including interleukin-1 beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), and granulocyte colony-stimulating factor (G-CSF).	Ditiocarb	17-21	interleukin 1 beta	Homo sapiens	128-146	
10029158-2	1999	The mechanism of DDTC-mediated chemoprotection is believed to involve the induction and release of several cytokines, including interleukin-1 beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), and granulocyte colony-stimulating factor (G-CSF).	Ditiocarb	17-21	interleukin 1 beta	Homo sapiens	148-156	
10029158-4	1999	Administration of IL-1 receptor antagonist (IL-1ra) to DDTC-treated hLTBMCs obviated the G-CSF induction profile and blocked the resultant colony proliferation, indicating that IL-1beta mediates DDTC-induced G-CSF release and hematopoiesis.	Ditiocarb	55-59	interleukin 1 beta	Homo sapiens	177-185	
10029158-4	1999	Administration of IL-1 receptor antagonist (IL-1ra) to DDTC-treated hLTBMCs obviated the G-CSF induction profile and blocked the resultant colony proliferation, indicating that IL-1beta mediates DDTC-induced G-CSF release and hematopoiesis.	Ditiocarb	195-199	interleukin 1 beta	Homo sapiens	177-185	
10029158-5	1999	IL-1beta mRNA levels were increased threefold over control following DDTC treatment of hLTBMCs, implying that DDTC induces IL-1beta at the level of transcription.	Ditiocarb	69-73	interleukin 1 beta	Homo sapiens	0-8	
10029158-5	1999	IL-1beta mRNA levels were increased threefold over control following DDTC treatment of hLTBMCs, implying that DDTC induces IL-1beta at the level of transcription.	Ditiocarb	69-73	interleukin 1 beta	Homo sapiens	123-131	
10029158-5	1999	IL-1beta mRNA levels were increased threefold over control following DDTC treatment of hLTBMCs, implying that DDTC induces IL-1beta at the level of transcription.	Ditiocarb	110-114	interleukin 1 beta	Homo sapiens	0-8	
10029158-5	1999	IL-1beta mRNA levels were increased threefold over control following DDTC treatment of hLTBMCs, implying that DDTC induces IL-1beta at the level of transcription.	Ditiocarb	110-114	interleukin 1 beta	Homo sapiens	123-131	
10029158-7	1999	These findings taken together strongly suggest that IL-1beta mediates the chemoprotective effects of DDTC.	Ditiocarb	101-105	interleukin 1 beta	Homo sapiens	52-60	
9545547-6	1998	Administration of diethyldithiocarbamate (DDC) inhibited induction of NF-kappa B and concomitantly the expression of IL-1 beta, IL-6, TNF-alpha as well as iNOS.	Ditiocarb	18-40	interleukin 1 beta	Homo sapiens	117-126	
9545547-6	1998	Administration of diethyldithiocarbamate (DDC) inhibited induction of NF-kappa B and concomitantly the expression of IL-1 beta, IL-6, TNF-alpha as well as iNOS.	Ditiocarb	42-45	interleukin 1 beta	Homo sapiens	117-126	
1322666-9	1992	These data suggest that the myeloprotective effects of DDTC may be mediated, at least in part, by the induction of TNF, IL-1 alpha, and IL-1 beta.	Ditiocarb	55-59	interleukin 1 beta	Homo sapiens	136-145